A new drug approved for treatment of ‘off phenomenon’ in Parkinsonism:
**Question:** A new drug approved for treatment of 'off phenomenon' in Parkinsonism:
A. Levodopa
B. Amantadine
C. Pramipexole
D. Ropinirole
**Correct Answer:** B. Amantadine
**Core Concept:**
The off phenomenon in Parkinson's disease is a temporary worsening of symptoms that occurs during the transition between periods of dopamine supplementation and its withdrawal. Dopamine is a neurotransmitter essential for motor control, and in Parkinson's disease, the decreased production of dopamine leads to motor symptoms like tremors, rigidity, and bradykinesia.
**Why the Correct Answer is Right:**
Amantadine (Option B) is an antiviral drug primarily used to treat influenza A. However, it also acts as a dopamine D1 and D2 receptor agonist, increasing dopamine levels in the brain and improving motor symptoms in Parkinson's disease patients. This is why amantadine is effective in treating the off phenomenon.
**Why Each Wrong Option is Incorrect:**
A. Levodopa (Option A) is the gold standard for treating Parkinson's disease, acting as a precursor to dopamine that is converted into dopamine in the brain. While it is effective in treating the motor symptoms, it does not address the off phenomenon directly.
C. Pramipexole (Option C) is a dopamine D2 receptor agonist, similar to amantadine, but it is not specifically approved for treating the off phenomenon. Pramipexole is primarily used for Parkinson's disease treatment.
D. Ropinirole (Option D) is another dopamine D2 receptor agonist, similar to pramipexole, but is also not specifically approved for treating the off phenomenon in Parkinson's disease.
**Clinical Pearl:** Amantadine is an example of a repurposed drug, where its off-label use in Parkinson's disease treatment demonstrates its efficacy in increasing dopamine levels and improving motor symptoms, especially in the off phenomenon. However, this does not replace the use of levodopa, which remains the primary medication for Parkinson's disease management.